A systematic review concluded that while genomic classifier (GC) tests could affect risk classifications or treatment choices for patients with localized prostate cancer (PCa), more research is ...

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and ...

Doctors often use tests like prostate-specific antigen levels and Gleason scores to help decide how to treat it. Genomic tests look at the genes of the cancer cells, which can give doctors a ...

A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer ... Prostate Score, have been developed ...

Currently, the U.S. is the major market for prognostic cancer ... scores were identified as suitable candidates for active surveillance. "Our findings show that the OncoAssure Prostate test ...

Currently, the US is the major market for prognostic cancer ... scores were identified as suitable candidates for active surveillance. "Our findings show that the OncoAssure Prostate test is ...

Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source ...

M.D., Ph.D., M.P.H., from the Moffitt Cancer Center in Tampa, Florida, and colleagues conducted a systematic review to summarize the impact of the Decipher, Oncotype DX Genomic Prostate Score (GPS ...

Men with higher risk scores on this test — OncoAssure Prostate — were more likely to have their cancer reoccur. Men with lower risk scores were identified as suitable for active surveillance ...

OncoAssure’s prostate test – a molecular clinical risk score – was found to predict risk for aggressive disease and cancer progression better than standard clinical and pathological information.

A companion lipid biomarker test, PCPro, will be used to identify patients who are likely to have a poor prognosis and may benefit from the combined treatment approach. Prostate cancer is the ...